Neuromyelitis optica following human papillomavirus vaccination

Til Menge; Bruce Cree; Andreas Saleh; Tim Waterboer; Achim Berthele; Sudhakar Reddy Kalluri; Bernhard Hemmer; Orhan Aktas; Hans Peter Hartung; Axel Methner; Bernd C. Kieseier

doi:10.1212/WNL.0b013e31825fdead

Neuromyelitis optica following human papillomavirus vaccination

Til Menge, Bruce Cree, Andreas Saleh, Tim Waterboer, Achim Berthele, Sudhakar Reddy Kalluri, Bernhard Hemmer, Orhan Aktas, Hans Peter Hartung, Axel Methner, Bernd C. Kieseier

Department of Neurology

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Original language	English
Pages (from-to)	285-287
Number of pages	3
Journal	Neurology
Volume	79
Issue number	3
DOIs	https://doi.org/10.1212/WNL.0b013e31825fdead
State	Published - 17 Jul 2012

Access to Document

10.1212/WNL.0b013e31825fdead

Cite this

@article{6b3122b5c7294f8fb34671890b0cf3c0,

title = "Neuromyelitis optica following human papillomavirus vaccination",

author = "Til Menge and Bruce Cree and Andreas Saleh and Tim Waterboer and Achim Berthele and Kalluri, {Sudhakar Reddy} and Bernhard Hemmer and Orhan Aktas and Hartung, {Hans Peter} and Axel Methner and Kieseier, {Bernd C.}",

note = "Funding Information: Study funding: The MS Center at the Department of Neurology, Heinrich Heine University, D{\"u}sseldorf, is supported in part by the Walter-and-Ilse-Rose-Stiftung and the German Ministry for Education and Research (BMBF, “German Competence Network Multiple Sclerosis,” KKNMS-BMBF). Funding Information: Disclosure: T. Menge has received honoraria and travel support from Bayer Schering Pharma, Biogen Idec, Teva, and Merck Serono. B. Cree received grant support from Genentech for a clinical trial of rituximab in NMO. A. Saleh and T. Waterboer report no disclosures. A. Berthele receives grant support from Bayer Healthcare for studies on NMO. S.R. Kalluri reports no disclosures. B. Hemmer received honoraria and grant support from Bayer Schering, Merck Serono, Biogen Idec, Teva, Roche, Genzyme, Genentech, and Novartis. O. Aktas has received consultancy fees/honoraria and travel grants from Bayer HealthCare, Merck Serono, and Novartis. H.-P. Hartung received honoraria, with approval of the rector of Heinrich Heine University and the CEO of Heinrich Heine University Hospital, for consulting and speaking from Bayer Schering pharma, Biogen Idec, Merck Serono, Genzyme, Novartis, Roche, and Teva Sanofi Aventis. A. Methner reports no disclosures. B.C. Kieseier received honoraria for lecturing and travel expenses for attending meetings and received financial research support from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva Pharmaceuticals. He has served or serves as consultant for Biogen Idec, Medac, Sanofi-Aventis, and Teva. Go to Neurology.org for full disclosures. ",

year = "2012",

month = jul,

day = "17",

doi = "10.1212/WNL.0b013e31825fdead",

language = "English",

volume = "79",

pages = "285--287",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Neuromyelitis optica following human papillomavirus vaccination

AU - Menge, Til

AU - Cree, Bruce

AU - Saleh, Andreas

AU - Waterboer, Tim

AU - Berthele, Achim

AU - Kalluri, Sudhakar Reddy

AU - Hemmer, Bernhard

AU - Aktas, Orhan

AU - Hartung, Hans Peter

AU - Methner, Axel

AU - Kieseier, Bernd C.

N1 - Funding Information: Study funding: The MS Center at the Department of Neurology, Heinrich Heine University, Düsseldorf, is supported in part by the Walter-and-Ilse-Rose-Stiftung and the German Ministry for Education and Research (BMBF, “German Competence Network Multiple Sclerosis,” KKNMS-BMBF). Funding Information: Disclosure: T. Menge has received honoraria and travel support from Bayer Schering Pharma, Biogen Idec, Teva, and Merck Serono. B. Cree received grant support from Genentech for a clinical trial of rituximab in NMO. A. Saleh and T. Waterboer report no disclosures. A. Berthele receives grant support from Bayer Healthcare for studies on NMO. S.R. Kalluri reports no disclosures. B. Hemmer received honoraria and grant support from Bayer Schering, Merck Serono, Biogen Idec, Teva, Roche, Genzyme, Genentech, and Novartis. O. Aktas has received consultancy fees/honoraria and travel grants from Bayer HealthCare, Merck Serono, and Novartis. H.-P. Hartung received honoraria, with approval of the rector of Heinrich Heine University and the CEO of Heinrich Heine University Hospital, for consulting and speaking from Bayer Schering pharma, Biogen Idec, Merck Serono, Genzyme, Novartis, Roche, and Teva Sanofi Aventis. A. Methner reports no disclosures. B.C. Kieseier received honoraria for lecturing and travel expenses for attending meetings and received financial research support from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva Pharmaceuticals. He has served or serves as consultant for Biogen Idec, Medac, Sanofi-Aventis, and Teva. Go to Neurology.org for full disclosures.

PY - 2012/7/17

Y1 - 2012/7/17

UR - http://www.scopus.com/inward/record.url?scp=84866102330&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e31825fdead

DO - 10.1212/WNL.0b013e31825fdead

M3 - Article

AN - SCOPUS:84866102330

SN - 0028-3878

VL - 79

SP - 285

EP - 287

JO - Neurology

JF - Neurology

IS - 3

ER -

Neuromyelitis optica following human papillomavirus vaccination

Access to Document

Other files and links

Cite this